Alnylam to Present Five-Year HELIOS-B Data at AHA and ISA 2026
Alnylam says it will present clinical and real-world data on vutrisiran at the AHA Scientific Sessions and International Symposium in 2026.
Related stories
Nasdaq single-stock trading halt continues, symbol not given — reason not given (10:35 AM ET)
Nasdaq kept trading halted in a single listed security (reason not given) at 10:35 AM ET.
M impact | EQUITY | Nov 03, 2026, 03:50 PM UTC
Apple CEO Says Timing of iPhone Supply-Demand Balance Is Uncertain
Apple’s CEO said the company cannot predict when iPhone supply and demand will balance.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Argentina’s Metalfor Seeks Preventive Insolvency Proceedings
The agricultural machinery manufacturer sought preventive insolvency proceedings after months of financial crisis and layoffs.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
LUX Infusion Acquires Be Well Memory’s Specialty Infusion Business
LUX Infusion says the acquisition expands access to clinician-led specialty infusion care in Nebraska.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Embraer Shares Rise More Than 4% After Greece KC-390 Order
Embraer shares rose more than 4% after Greece placed an order for KC-390 aircraft.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Minda Corporation Q2 Revenue Rises 42.6% to Rs 2,189 Crore
Consolidated operating revenue increased year on year from Rs 1,535 crore in the corresponding period last year. EV products accounted for 35% of new orders.
M impact | EQUITY | Nov 03, 2026, 03:33 PM UTC